Chardan Capital Cuts Century Therapeutics (NASDAQ:IPSC) Price Target to $11.00

Century Therapeutics (NASDAQ:IPSC) had its price target decreased by Chardan Capital from $17.00 to $11.00 in a research note issued to investors on Thursday,Benzinga reports. Chardan Capital currently has a buy rating on the stock.

Other research analysts have also issued reports about the company. HC Wainwright lowered their price target on Century Therapeutics from $9.00 to $5.00 and set a “buy” rating for the company in a research report on Wednesday. Rodman & Renshaw began coverage on Century Therapeutics in a research report on Thursday, August 8th. They set a “buy” rating and a $6.00 price target for the company. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $11.60.

Century Therapeutics Trading Down 0.7 %

IPSC stock traded down $0.01 during midday trading on Thursday, hitting $1.45. 236,920 shares of the company’s stock were exchanged, compared to its average volume of 261,464. The business has a 50-day simple moving average of $1.52 and a two-hundred day simple moving average of $2.23. The stock has a market capitalization of $122.84 million, a PE ratio of -0.79 and a beta of 1.41. Century Therapeutics has a 1-year low of $1.14 and a 1-year high of $5.51.

Century Therapeutics (NASDAQ:IPSC) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.08. Century Therapeutics had a negative return on equity of 60.60% and a negative net margin of 6,434.23%. The business had revenue of $0.79 million during the quarter, compared to analyst estimates of $0.47 million. During the same period last year, the business posted ($0.55) earnings per share. As a group, research analysts expect that Century Therapeutics will post -1.8 EPS for the current fiscal year.

Institutional Trading of Century Therapeutics

A number of institutional investors have recently bought and sold shares of IPSC. Jacobs Levy Equity Management Inc. increased its position in shares of Century Therapeutics by 191.0% during the first quarter. Jacobs Levy Equity Management Inc. now owns 293,941 shares of the company’s stock worth $1,229,000 after purchasing an additional 192,915 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Century Therapeutics by 110.1% during the second quarter. Bank of New York Mellon Corp now owns 149,000 shares of the company’s stock worth $380,000 after purchasing an additional 78,088 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of Century Therapeutics by 141.7% during the second quarter. Dimensional Fund Advisors LP now owns 75,315 shares of the company’s stock worth $192,000 after purchasing an additional 44,155 shares in the last quarter. Rhumbline Advisers increased its position in shares of Century Therapeutics by 56.0% during the second quarter. Rhumbline Advisers now owns 52,466 shares of the company’s stock worth $134,000 after purchasing an additional 18,828 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new stake in shares of Century Therapeutics during the third quarter worth about $27,000. 50.20% of the stock is owned by hedge funds and other institutional investors.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.